Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial-Reference-Cited by-同舟云学术

Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial

Published:2022-06-24 Issue:12 Volume:21 Page:1495-1503
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Hashimoto Yoichiro¹,Komori Mika²,Tanji Yuka²,Ozeki Akichika²,Hirata Koichi³

Affiliation:

1. Department of Neurology, Kumamoto City Hospital, Kumamoto, Japan

2. Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan

3. Headache Center, Dokkyo Medical University, Mibu, Japan

Funder

Eli Lilly Japan K.K. and Daiichi Sankyo Company, Limited

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2078302

Reference26 articles.

1. Prevalence of Migraine in Japan

2. Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study

3. Social burden of people with the migraine diagnosis in Japan: evidence from a population-based cross-sectional survey

4. Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme

5. Japanese Society of Neurology and the Japanese Headache Society. Clinical practice guideline for chronic headache. 2013 [cited 2021 Mar 30]. Available from: https://www.neurology-jp.org/guidelinem/ch/documents/preface.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database;Expert Opinion on Drug Safety;2024-07-10

2. Headache Education by E-Learning Through Social Networking Services (Social Media);Journal of Healthcare Leadership;2023-11

3. Developing an Artificial Intelligence-Based Pediatric and Adolescent Migraine Diagnostic Model;Cureus;2023-08-30

4. The 5-HT1F receptor as the target of ditans in migraine — from bench to bedside;Nature Reviews Neurology;2023-07-12

5. Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study;Journal of Pain Research;2023-05